MENLO PARK, Calif.,
Dec. 2, 2014 /PRNewswire/ --
BioPharmX Corporation (OTCQB: BPMX), a biotechnology company
focused on the development of novel drug delivery products to
address unmet needs in large, well-defined and underserved markets,
today announced that it has submitted a request for a pre-IND
(Investigational New Drug) meeting to the U.S. Food and Drug
Administration (FDA) for the company's topical antibiotic acne
compound currently under development. The company plans to
follow up by submitting a briefing package on a later date in
support of a pre-IND meeting to review the company's proposed
strategy and plan for conducting safety and toxicology studies and
human clinical trials required for approval of its acne
product.
"This marks a major step in BioPharmX's plan to introduce
products that target large, multi-billion-dollar markets," said
Jim Pekarsky, chief executive
officer and co-founder of BioPharmX. "Leading oral antibiotic
acne products have potential side effects, and, as we move forward,
we are hopeful that the initial pre-clinical results we've seen
thus far for our topical antibiotic acne solution will eventually
lead to an approved alternative," said Pekarsky. "Longer
term, we believe this potential product could be just one leg of a
multi-faceted growth strategy BioPharmX has planned that is focused
on the women's health, dermatology, and otolaryngology health care
segments."
BioPharmX announced on November 10,
2014 that the company had secured up to $12 million in a Series A private placement
(Series A). The total amount includes $2 million in funding subject to the company
achieving certain milestones. The proceeds are being used to
advance the company's pipeline of products in the fields of women's
health and dermatology and to fund the near-term launch and
commercialization of the company's women's health product.
About BioPharmX Corporation
BioPharmX Corporation
(OTCQB: BPMX) is a Silicon Valley-based biotechnology company,
which seeks to provide innovative products through unique,
proprietary platform technologies for prescription,
over-the-counter ("OTC"), and supplement applications in the
fast-growing health and wellness markets, including women's health,
dermatology, and otolaryngology (ears, nose & throat). To
learn more about BioPharmX, visit www.BioPharmX.com.
Forward-Looking Statements
Statements in this news
release relating to the business of BioPharmX, which are not
historical facts, are "forward-looking statements." These
forward-looking statements may be identified by words such as
"expect," "anticipate," "believe," or similar expressions that are
intended to identify such forward-looking statements. All
forward-looking statements are expressly qualified in their
entirety by this cautionary statement and the risks and other
factors detailed in the company's filings with the Securities and
Exchange Commission (SEC). Given these risks and
uncertainties, you are cautioned not to place undue reliance on
such forward-looking statements. The forward-looking
statements included in this news release are made only as of the
date hereof and the company undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
may be required under applicable securities law.
BioPharmX is a trademark of BioPharmX Corporation.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/biopharmx-corporation-announces-submission-of-pre-ind-meeting-request-to-the-us-fda-for-its-topical-acne-solution-300002864.html
SOURCE BioPharmX Corporation